Clinical Trials

Inclusion Criteria:

1. People with upper GI symptoms (e.g., due to functional dyspepsia or diabetes mellitus)
2. Able to provide written informed consent before participating in the study
3. Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Exclusion Criteria:

1. Severe nausea or vomiting, which may preclude study assessments
2. Use of medications that, in the opinion of the investigator have the potential, to alter GI motility (e.g., narcotics, medications with significant anticholinergic effects, prokinetic agents) and were not discontinued within 4 half-lives prior to either (i.e., clinical or research) scintigraphy. See the attached pdf file of the clinical protocol for a comprehensive list of medications that interfere with GI transit.
3. Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study.  History of or ongoing inflammatory bowel disease (e.g, Crohn’s disease or ulcerative colitis). However, participants with microscopic or collagenous colitis will be eligible to participate
4. Prior gastric or major intestinal (i.e., resection of > 50 cm) or colonic surgery (i.e., hemi or subtotal colectomy)
5. Participants who are allergic to eggs or decline to consume milk
6. History of radiation therapy to the abdomen
7. Positive pregnancy test